199 related articles for article (PubMed ID: 26788345)
21. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis.
Zintzaras E; Kitsios GD; Papathanasiou AA; Konitsiotis S; Miligkos M; Rodopoulou P; Hadjigeorgiou GM
Clin Ther; 2010 Feb; 32(2):221-37. PubMed ID: 20206780
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients.
Inoue Y; Uchimura N; Kuroda K; Hirata K; Hattori N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):251-7. PubMed ID: 22036917
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Comparison of the Efficacies of 5 First-Line Drugs for Primary Restless Leg Syndrome.
Zhang N; Li Y; Lv Y; Xu L; Chen J; Liu H; Li L; Zheng Q
J Clin Pharmacol; 2019 Sep; 59(9):1177-1187. PubMed ID: 31106855
[TBL] [Abstract][Full Text] [Related]
24. Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease).
Ondo WG; Grieger F; Moran K; Kohnen R; Roth T
J Clin Sleep Med; 2016 Jan; 12(1):63-70. PubMed ID: 26446245
[TBL] [Abstract][Full Text] [Related]
25. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial.
Dauvilliers Y; Benes H; Partinen M; Rauta V; Rifkin D; Dohin E; Goldammer N; Schollmayer E; Schröder H; Winkelman JW
Am J Kidney Dis; 2016 Sep; 68(3):434-43. PubMed ID: 26851201
[TBL] [Abstract][Full Text] [Related]
26. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
27. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study.
Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H
Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
Lal R; Sukbuntherng J; Luo W; Tovera J; Lassauzet ML; Cundy KC
J Clin Pharmacol; 2013 Jan; 53(1):29-40. PubMed ID: 23400741
[TBL] [Abstract][Full Text] [Related]
29. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation.
Winkelman JW; Mackie SE; Mei LA; Platt S; Schoerning L
Sleep Med; 2016 Aug; 24():18-23. PubMed ID: 27810181
[TBL] [Abstract][Full Text] [Related]
30. Dopamine agonists for restless legs syndrome.
Scholz H; Trenkwalder C; Kohnen R; Riemann D; Kriston L; Hornyak M
Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD006009. PubMed ID: 21412893
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial.
Trenkwalder C; Benes H; Poewe W; Oertel WH; Garcia-Borreguero D; de Weerd AW; Ferini-Strambi L; Montagna P; Odin P; Stiasny-Kolster K; Högl B; Chaudhuri KR; Partinen M; Schollmayer E; Kohnen R;
Lancet Neurol; 2008 Jul; 7(7):595-604. PubMed ID: 18515185
[TBL] [Abstract][Full Text] [Related]
32. Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?
Kume A
Neuropsychiatr Dis Treat; 2014; 10():249-62. PubMed ID: 24523590
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset.
Allen RP; Ritchie SY
Sleep Med; 2008 Dec; 9(8):899-902. PubMed ID: 18024167
[TBL] [Abstract][Full Text] [Related]
34. Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome.
Inoue Y; Hirata K; Hoshino Y; Yamaguchi Y
Sleep Med; 2021 Sep; 85():138-146. PubMed ID: 34329897
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.
Kushida CA; Becker PM; Ellenbogen AL; Canafax DM; Barrett RW;
Neurology; 2009 Feb; 72(5):439-46. PubMed ID: 19188575
[TBL] [Abstract][Full Text] [Related]
36. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.
Bogan RK; Fry JM; Schmidt MH; Carson SW; Ritchie SY;
Mayo Clin Proc; 2006 Jan; 81(1):17-27. PubMed ID: 16438474
[TBL] [Abstract][Full Text] [Related]
37. The DIalysis Symptom COntrol-Restless Legs Syndrome (DISCO-RLS) Trial: A Protocol for a Randomized, Crossover, Placebo-Controlled Blinded Trial.
Collister D; Pohl K; Herrington G; Lee SF; Rabbat C; Tennankore K; Zimmermann D; Tangri N; Wald R; Manns B; Suri RS; Nadeau-Fredette AC; Goupil R; Silver SA; Walsh M
Can J Kidney Health Dis; 2020; 7():2054358120968959. PubMed ID: 33294203
[TBL] [Abstract][Full Text] [Related]
38. Gabapentin Enacarbil: A Review in Restless Legs Syndrome.
Kim ES; Deeks ED
Drugs; 2016 May; 76(8):879-87. PubMed ID: 27146056
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points--data from the ropinirole clinical trial programme.
Giorgi L; Ritchie SY; Kirsch JM
Curr Med Res Opin; 2006 Oct; 22(10):1867-77. PubMed ID: 17022844
[TBL] [Abstract][Full Text] [Related]
40. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
